KOWEI Pharmaceuticals -B (02171): The abstract of CT071 has been accepted for presentation at the 2025 EHA Annual Meeting as a poster.

"China Fortune Financial News APP News, KEJ Pharmaceutical-B (02171) announced that the summary of the research results of the clinical trial (NCT06407947) initiated by researchers using CT071 (an autologous CAR-T cell product targeting GPRC5D) for the treatment of newly diagnosed multiple myeloma (NDMM) has been accepted by the 2025 European Hematology Association Annual Meeting (EHA) and will be presented at the poster exhibition. The abstract and further information will be announced after 15:30 on May 14, 2025 Central European Time."